Welcome to our dedicated page for Vaxcyte news (Ticker: PCVX), a resource for investors and traders seeking the latest updates and insights on Vaxcyte stock.
Vaxcyte, Inc. (Nasdaq: PCVX) is a clinical-stage vaccine innovation company focused on broad-spectrum bacterial vaccines, and its news flow reflects progress across multiple pneumococcal conjugate vaccine programs and related manufacturing and regulatory milestones. Company announcements frequently highlight clinical trial updates for VAX-31, a 31-valent pneumococcal conjugate vaccine (PCV) candidate advancing to a Phase 3 adult program and being evaluated in a Phase 2 infant study, as well as VAX-24, a 24-valent PCV candidate in a Phase 2 infant study.
Investors and observers following PCVX news can expect detailed coverage of Phase 2 and Phase 3 study designs, topline safety, tolerability and immunogenicity data, and dose-selection decisions for both adult and pediatric indications. Recent releases have described the OPUS adult Phase 3 pivotal noninferiority trial for VAX-31, the multi-stage VAX-31 infant dose-finding study, and positive topline results from the VAX-24 infant Phase 2 trial, including IgG and opsonophagocytic assay responses compared with existing PCVs.
Vaxcyte’s news also covers regulatory interactions and designations, such as the U.S. Food and Drug Administration’s Breakthrough Therapy designation for VAX-31 in adults and its expansion to include prevention of pneumonia caused by Streptococcus pneumoniae. In addition, the company reports on manufacturing and supply-chain developments, including a dedicated manufacturing suite at Lonza and a long-term agreement with Thermo Fisher Scientific’s Patheon unit to provide fill-finish capacity in Greenville, North Carolina as part of its U.S. commercial supply strategy.
Other updates include business and financial results, capital allocation priorities, early-stage pipeline decisions involving candidates such as VAX-A1 and VAX-GI, and governance changes such as board and executive appointments. For readers tracking PCVX, this news page offers an ongoing view into Vaxcyte’s clinical progress, regulatory pathway, manufacturing readiness and corporate developments around its pneumococcal and broader bacterial vaccine pipeline.
Vaxcyte, Inc. (Nasdaq: PCVX) announced an additional $3.2 million grant from CARB-X, bringing total potential funding to $29.7 million for the development of its vaccine candidate, VAX-A1. This funding aims to enable the Investigational New Drug (IND) application for VAX-A1, a vaccine targeting Group A Streptococcus, which causes 700 million cases of illness annually. The vaccine is critical in addressing antibiotic resistance and reducing morbidity and mortality related to this widespread infection.
Vaxcyte, Inc. (Nasdaq: PCVX), a company focused on next-generation vaccines, will present at the Jefferies Virtual Healthcare Conference on June 3, 2021, at 4:00 PM ET. The event aims to showcase its innovative vaccine solutions designed to combat severe infectious diseases.
The presentation will be accessible via the company’s website, with a replay available for 30 days. Vaxcyte is known for its advanced cell-free protein synthesis platform and its lead candidate, VAX-24, targeting invasive pneumococcal disease.
Vaxcyte, Inc. (Nasdaq: PCVX) reported Q1 2021 financial results and updates on its vaccine pipeline. As of March 31, 2021, it had $370.9 million in cash. R&D expenses decreased to $17.3 million, while G&A expenses rose to $5.9 million, resulting in a net loss of $21.2 million. The company is progressing with its 24-valent pneumococcal vaccine, VAX-24, aiming to submit an IND application to the FDA by mid-2022. Vaxcyte also appointed Janet Graesser as Vice President of Corporate Communications, enhancing its strategic communications.
Vaxcyte announced the publication of preclinical data for its investigational VAX-24 vaccine in Vaccine, showing that all 24-valent serotypes in VAX-24 elicited robust immune responses compared to existing vaccines. This 24-valent pneumococcal conjugate vaccine targets strains not covered by the current 13-valent vaccine, addressing a significant unmet medical need in preventing invasive pneumococcal disease. Vaxcyte plans to submit an Investigational New Drug application to the FDA for VAX-24, advancing towards clinical trials.
Vaxcyte, Inc. (Nasdaq: PCVX) announced its participation in the BofA Securities 2021 Health Care Conference set for May 13, 2021, at 3:30 PM ET. The event will feature company management presenting the latest developments in their innovative vaccines aimed at combating infectious diseases. A live webcast will be accessible via their official website, with a replay available for 30 days post-conference. Vaxcyte is noted for its advanced vaccine candidates including VAX-24, addressing pneumococcal disease, and VAX-XP for broader strain coverage.
Vaxcyte, Inc. (Nasdaq: PCVX) announced its participation in the 20th Annual Needham Virtual Healthcare Conference on April 12, 2021, at 1:30 p.m. ET. The event aims to showcase Vaxcyte's innovative vaccine development efforts, including its lead candidate, VAX-24, a preclinical pneumococcal conjugate vaccine designed for preventing invasive pneumococcal disease. A live webcast will be available through the company's website, with a replay offered for 30 days post-conference. Vaxcyte is focused on creating novel vaccines to address common infectious diseases globally.
Vaxcyte, Inc. (Nasdaq: PCVX) reported its financial results for Q4 and full year 2020, highlighting a net loss of $20.7 million for Q4 and $89.2 million for the year. The company announced a revised timeline for its VAX-24 IND application submission, now expected between January and June 2022, due to manufacturing constraints. Key advancements included new immunogenicity data for its VAX-XP program and the final candidate nomination for VAX-A1. Vaxcyte's cash position increased to $386.2 million, supported by its IPO and Series D financing in 2020.
Vaxcyte, Inc. (Nasdaq: PCVX) will report its financial results for Q4 and the full year 2020 after market close on March 29, 2021. A conference call is scheduled for 4:30 p.m. ET to discuss the results and provide a business update. Vaxcyte develops innovative vaccines aimed at preventing major infectious diseases, leveraging its cell-free protein synthesis platform, XpressCF. The lead candidate, VAX-24, is a preclinical 24-valent pneumococcal conjugate vaccine. Additional candidates include VAX-XP, VAX-A1, and VAX-PG.
Vaxcyte published preclinical data for its novel Group A Streptococcus vaccine candidate, VAX-A1, in the journal Infectious Microbes & Diseases. This vaccine aims to combat Group A Strep, a leading cause of bacterial infections, including strep throat, which significantly contributes to global antibiotic prescriptions. The study exhibited that the vaccine could effectively protect against Group A Strep infections in mouse models without cross-reactivity to human tissues. Vaxcyte is advancing toward a global health solution amid rising antibiotic resistance concerns.
Vaxcyte, Inc. has announced the promotion of Andrew Guggenhime to President and Chief Financial Officer, effective January 1, 2021. This transition reflects the company's leadership evolution as it aims to scale operations and advance its vaccine pipeline, especially the pneumococcal vaccine candidate VAX-24. Guggenhime, who joined Vaxcyte in May 2020, brings over two decades of financial and operational experience in the healthcare sector.
Vaxcyte focuses on developing innovative vaccines to combat infectious diseases globally, leveraging its cell-free protein synthesis platform for vaccine creation.
FAQ
What is the current stock price of Vaxcyte (PCVX)?
What is the market cap of Vaxcyte (PCVX)?
